|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||37.43 / 45.86|
A federal judge has banned the sale of Regeneron's cholesterol-lowering drug Praluent, handing a surprise and overwhelming victory to Amgen and its competing drug Repatha in a long-running patent lawsuit.
European shares open with a defensive tone ahead of U.S. December nonfarm payrolls; Sanofi slumps on the Praluent injunction.
Sanofi and Boehringer Ingelheim confirmed today that the strategic transaction signed in June 2016, which consists of an exchange of Sanofi's animal health business (Merial) and Boehringer Ingelheim's consumer...
Actelion's CEO has held control at the company he founded, but its largest shareholder has ties with Johnson & Johnson.
U.S. stock futures post slight losses as investors await data on U.S. growth and durable goods; Carl Icahn is named special adviser to President-elect Donald Trump on overhauling federal regulations.
Shares in the biotech firm hit a record high Thursday after confirming 'exclusive' talks with Johnson & Johnson.
European stocks are likely to post modest losses Thursday as a slower holiday trading pace takes over regional markets.
The Dow Jones Industrial Average's steady path to its 20,000 milestone hit the pause button on Wednesday after a meandering day of slight losses.
Stocks hold slightly lower on Wednesday as the Dow Jones Industrial Average hovers around 40 points below its 20,000 milestone.
The Swiss biotech says it's in exclusive talks with J&J about a possible 'strategic transaction.'
Shares in the Swiss biotech surge amid reports that Sanofi could use a 'CVR' technique to enhance the potential bid price.
While there is deep uncertainty about how politics will affect the health care sector in the new year, analysts seem excited about some opportunities in pharmaceuticals.
Meanwhile, Astrazeneca's shares fall as its head of oncology leaves for the smaller biotech company.
The success of its first Star Wars spin-off and other 'blockbuster-level' film releases make Disney a stock to own, according to Bank of America.
The negative investor sentiment for health care stocks in 2016 presented a particularly challenging environment to accomplish anything well. Each of these CEOs met the challenge and succeeded.
The Dow Jones Industrial Average held slight weekly gains on Friday afternoon even in a down day for Wall Street.
Stocks rise on Friday, putting the Dow Jones Industrial Average one step closer to the psychologically important 20,000 level.
U.S. stock futures are mixed while the dollar surges as global markets adjust to higher U.S. interest rates; Facebook plans to fact-check its news; Adobe's earnings top forecasts.
European stocks are set to book another solid weekly advance amid global market adjustments to the new Fed outlook.
Actelion stocks surged higher in Zurich amid speculation that France's Sanofi may make a formal approach for the Swiss biotech.
Actelion was too pricey. Now J&J is looking for another acquisition.
Jim Cramer comments on Johnson & Johnson's move to abandon merger talks with Actelion.
U.S. stock futures are mixed ahead of a decision on interest rates and fresh economic forecasts from the Fed; tech giants meet with Donald Trump; IBM's Rometty promises jobs.
Actelion confirms the end of talks with J&J over a $27 billion takeover, and market focus shifts to France's Sanofi.
European stocks are set to open lower Wednesday ahead of the Fed's final policy meeting of 2016.
U.S. stock futures trade flat following another record close for the Dow; Amazon reportedly envisions opening 2,000 brick-and-mortar grocery stores; Apple Watch sales set a record, Apple CEO says.
European markets are set for a positive open Tuesday after Asia traders booked their best single-day gains in two weeks.
Actelion shares are on the rise again on reports of a potential counter-bid from France's Sanofi.
Sanofi Genzyme, the specialty care global business unit of Sanofi, today announced the initiation of the ICARIA-MM Phase III trial of isatuximab, an investigational anti-CD38 monoclonal antibody being studied for the...
Actelion shares traded sharply lower Tuesday following reports it's looking at strategies that would keep it independent from a $17 billion approach from Johnson & Johnson.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.